Paq Therapeutics, Inc.
Clinical trials sponsored by Paq Therapeutics, Inc., explained in plain language.
-
New hope for Hard-to-Treat cancers: experimental drug targets KRAS G12D mutation
Disease control Recruiting nowThis early-phase study tests an experimental drug called PT0253 in adults with advanced solid tumors that have a specific genetic change (KRAS G12D mutation). The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 115 participa…
Phase: PHASE1 • Sponsor: PAQ Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
New hope for Hard-to-Treat cancers: experimental drug PT0511 targets KRAS mutations
Disease control Recruiting nowThis early-phase study tests a new drug called PT0511 in adults with advanced solid tumors that have a KRAS mutation or amplification, including colorectal, pancreatic, and lung cancers. The main goals are to check safety, find the best dose, and see how the drug works alone or w…
Phase: PHASE1 • Sponsor: PAQ Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 03:49 UTC